Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
Yuqin Song(Peking University), Jun Zhu(Peking University), Shuhua Yi(Chinese Academy of Medical Sciences & Peking Union Medical College), Daobin Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Renbin Zhao(Kunming University of Science and Technology), Zhengguang Lu(Florida State University), Yu Hu(Wuhan Union Hospital), Jie Jin(Beijing Institute of Technology), Yongping Song(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Ting Liu(Chinese PLA General Hospital), Lihong Liu(Hebei Medical University), Wei Xu(Jiangsu Province Hospital), Zhixin Xu(East China Normal University), Song Lin(Capital Medical University), Huaqiang Zhu(Zhejiang Pharmaceutical College), Zhiming Li(Anhui Medical University)
Cited by 16
Related Papers
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
|Science Immunology|2020|555
Magnetic brightening and control of dark excitons in monolayer WSe2
|Nature Nanotechnology|2017|441
Targeting CD47 for cancer immunotherapy
|Journal of Hematology & Oncology|2021|342
Association analyses identify six new psoriasis susceptibility loci in the Chinese population
|Nature Genetics|2010|317
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296